Hepatitis is a serious disorder in which liver cells become inflamed. The inflammation usually occurs because of a virus. It can also be caused by an overactive immune system, and from drugs, alcoholism, chemicals, and environmental toxins. Viral hepatitis usually appears as type A, B, or C, although hepatitis D and E have been reported.
Type A, the most common form of viral hepatitis, often affects school-aged children. The disease is transmitted by contaminated food or water, or contact with a person ill with hepatitis A. The hepatitis A virus is shed in the stools of an infected person during the incubation period of 15 - 45 days before symptoms occur and during the first week that the person feels sick. Blood and other body fluids may also carry the infection. The virus does not stay in the body after the infection has resolved, and, unlike hepatitis types B and C, there is no "carrier" state (a person who spreads the disease to others but does not become ill).
Hepatitis types B and C affect people of all ages. Most people who become infected with hepatitis B get rid of the virus within 6 months. This type of short infection is known as an "acute" case of hepatitis B. About 10% of people infected with the hepatitis B virus develop a chronic, life-long infection. People with chronic infection may or may not have symptoms. Those who do not develop symptoms are referred to as carriers. Having chronic hepatitis B increases your chance of permanent liver damage, including cirrhosis (scarring of the liver) and liver cancer.
Anyone who has chronic hepatitis B is also susceptible to infection with another strain of viral hepatitis known as hepatitis D (formerly called delta virus). Hepatitis D virus can only infect cells if the hepatitis B virus (HBV) is present. Injection drug users with hepatitis B have the greatest risk of developing the infection. Individuals who are infected with both HBV and hepatitis D are more likely to develop cirrhosis or liver cancer than patients who only have HBV.
Hepatitis E is uncommon in the United States. This disease is primarily spread through food or water that is contaminated by feces from an infected person. There is no vaccine for hepatitis E. The only way to prevent the disease is to reduce the risk of exposure to the virus. Hepatitis E usually resolves without treatment, within several weeks to months.
Acute Hepatitis
Chronic Hepatitis
Chronic hepatitis may not be preceded by an acute (immediate) phase, or the acute symptoms may be quite subtle and go unnoticed. Some people with hepatitis C feel only mild ongoing fatigue and, perhaps, whole-body itching. The virus is then found by a blood test.
Hepatitis A is usually transmitted from feces on unwashed hands (putting dirty hands into the mouth) and by ingesting contaminated food and water (for example, seafood from sewage contaminated water). It can also be transmitted through close contact with someone who has the virus.
Hepatitis B and C are transmitted via blood. Therefore, these forms of the virus can be transmitted by people who have a blood transfusion, use intravenous (IV) drugs with contaminated needles, and through sexual activity. In as many as 40% of the cases of hepatitis C, the specific cause of transmission is unknown. Blood and blood products that are used for transmission can now be tested for both hepatitis B and C.
Hepatitis A
Hepatitis B
Hepatitis C
First, your doctor will ask you questions to assess your risk for the different types of viral hepatitis. Questions will include whether you:
Next, your doctor will examine your abdomen carefully, including palpating your liver and spleen to see if either is enlarged or tender. Then, a blood test will be performed to assess your liver function and test for antibodies against the specific hepatitis viruses. Your doctor will likely request a urine test as well. For chronic hepatitis, a liver biopsy may be required, which must be done under general anesthesia. A liver biopsy is particularly important if you have chronic hepatitis C because this test assesses the degree of liver damage, which can occur even if you have no symptoms.
Hepatitis A
Transmission of the virus can be reduced by faithfully following these practices, particularly in child daycare facilities and other institutions involving close contact with people:
Hepatitis B and C
Preventive measures are the same for both hepatitis B and C.
Immunization
Hepatitis A
Candidates for the hepatitis A vaccine include:
Hepatitis B
There are several inactivated vaccines available for hepatitis B. Immunization provides the only definitive protection against hepatitis B. The hepatitis B vaccine is one of the recommended childhood immunizations, and is now part of routine pediatric care in the United States. Adults who are at higher risk, should also be vaccinated:
Hepatitis C
There is no vaccine for hepatitis C, but immunoglobulin helps protect against it after blood transfusions. Periodic doses in sexual partners of an infected person may also help to give protection.
Acute Hepatitis
The goals for treating acute viral hepatitis include:
There are no medications to treat acute hepatitis, although your doctor may recommend drugs that alleviate some of the symptoms. Most cases of acute hepatitis are mild and do not even require hospitalization. Only people who are at high risk for complications, such as pregnant women, the elderly, people with serious underlying medical conditions, or those who become significantly dehydrated from excessive nausea and vomiting need to be hospitalized. The very rare cases of acute hepatitis that lead to liver failure (called fluminant acute hepatitis) not only require hospitalization but also need liver transplantation.
Chronic Hepatitis
The goals for treatment of chronic viral hepatitis include:
There are several medications from which your doctor will choose to help achieve these goals.
Because the conventional medications used to treat chronic hepatitis have a lot of unpleasant side effects, many people with this condition turn to alternative medical therapies instead. CAM practices that may help boost your immune function and help make you feel stronger and less tired while taking conventional medications include herbal and vitamin supplements, homeopathy, acupuncture, and massage therapy. Make sure that your health care providers know that you have hepatitis so that the necessary precautions can be taken to avoid spread of the virus.
Your doctor will talk with you about steps you can take to keep from spreading the virus. For hepatitis A, these include:
For hepatitis B and C, these measures include:
If you are traveling to a high-risk country, take the following precautions:
Other general lifestyle measures to take include:
Interferons -- This group of medications are natural proteins that activate immune functions in the body and have anti-viral properties. Examples of interferon medications include Roferon-A, Intron-A, Rebetron, Alferon-N, and Peg-Intron. These drugs do not work for everyone who takes them, but for those who do respond, the possible benefits include:
Drawbacks for this class of drugs include:
Corticosteroids -- Corticosteroids may be used in the early stages of chronic hepatitis to enhance the effects of interferon. Corticosteroids include prednisone (Deltasone) and methylprednisolone (Medrol).
Nucleoside Analogues -- This class of drugs, including lamivudine (Epivir), ribavirin (Rebetol), are used to stop replication of the virus. Advantages of lamivudine, often used to treat chronic hepatitis B, over interferon include:
Like interferon, nucleoside analogues can lose their effectiveness over time.
Ribavirin is often used in combination with interferon for chronic hepatitis C. Although ribavirin improves the response rate for those with hepatitis C, side effects from the interferon become more likely when this second drug is added. Potential side effects from the ribavirin itself include:
Newer nucleoside analogues developed for hepatitis treatment include adefovir (Hepsera) and entecavir (Baraclude). Adefovir is used in people with hepatitis B who do not respond to lamivudine. Entecavir was approved by the U.S. Food and Drug Administration in 2005 for treatment of hepatitis B. Entecavir may cause symptoms of hepatitis to worsen once medication is discontinued. Talk to your doctor about the best medicine for your condition.
People with the following conditions may qualify for a liver transplant:
Five-year survival rate after liver transplantation is 60 - 80%. Unfortunately, in about 50% of those with chronic hepatitis who receive a liver transplant, the infection recurs.
Although no special diets have been shown to help treat acute hepatitis, eating small snacks during the day, with larger ones in the morning, may be recommended. Eating this way helps optimize digestion, prevent weight loss, and reduce nausea. Following these nutritional tips may help improve general health and well-being:
You may address nutritional deficiencies with the following supplements:
Herbs are generally a safe way to strengthen and tone the body's systems. As with any therapy, you should work with your health care provider to get your problem diagnosed before starting any treatment. You may use herbs as dried extracts (capsules, powders, teas), glycerites (glycerine extracts), or tinctures (alcohol extracts). Unless otherwise indicated, you should make teas with 1 tsp. herb per cup of hot water. Steep covered 5 - 10 minutes for leaf or flowers, and 10 - 20 minutes for roots. Drink 2 - 4 cups per day. You may use tinctures alone or in combination as noted.
While research in China has shown some promise in treating hepatitis B, few acupuncturists in the United States provide treatment for this or other forms of hepatitis. Acupuncture is generally used in China and other countries to boost the immune system of those with hepatitis.
There has been some concern that patients could contract hepatitis from dirty needles or infected practitioners. However, there have been no reported incidents of infection in the U.S. Because of the customary, and in many instances legally mandated, use of sterile, disposable needles by acupuncturists in the U.S., there is virtually no risk of contracting hepatitis from acupuncture therapy here or other countries with similar standards and safe practices.
Therapeutic massage may help enhance immune function.
Few studies have examined the effectiveness of specific homeopathic remedies. A professional homeopath, however, may recommend one or more of the following treatments for viral hepatitis based on his or her knowledge and clinical experience. Before prescribing a remedy, homeopaths take into account a person's constitutional type -- your physical, emotional, and intellectual makeup. An experienced homeopath assesses all of these factors when determining the most appropriate remedy for a particular individual.
Traditional Chinese Medicine (TCM)
Traditional Chinese Medicine (TCM) is a range of traditional medical practices originating in China that developed over several thousand years. When assessing a person with hepatitis, a TCM practitioner might make one of the following diagnoses:
Once the diagnosis is established, the practitioner is likely to use acupuncture, moxibustion (a burning of an herb called mugwort over acupuncture sites), and herbal drugs to address the imbalances of hepatic qi (energy) and yin-yang (balance).
If an individual is at increased risk of contracting hepatitis or if they have already been infected with any form of the hepatitis virus, a doctor will recommend the hepatitis B vaccine. A vaccine is also available for hepatitis A.
Food handlers should be extremely careful of contracting hepatitis A, and health care workers should always exercise universal precautions to avoid contraction or transmission of hepatitis B or C.
Support groups are available for people with chronic hepatitis B or C. It is often difficult to cope with having this particular disease. Talking with people who also have this condition in a formal setting is often very helpful. Check with your doctor or hospital to locate a support group near you.
Hepatitis B and C can be transmitted during pregnancy or childbirth. Women who are pregnant or planning to become pregnant soon cannot take interferon or nucleoside analogues.
Because the liver processes many types of medications, you will most likely be advised to stop taking all drugs other than those recommended for treatment of hepatitis.
Similarly, certain herbs and supplements are known to cause harm to the liver:
In the acute phase of hepatitis, jaundice generally disappears in 2 - 8 weeks. Occasionally, hospitalization is necessary (for example, if you become significantly dehydrated), but most people completely recover. Full recovery of normal liver function tests, however, may take several months.
Rare yet serious complications of acute hepatitis include aplastic anemia (when the bone marrow makes no new cells) which can be fatal, pancreatitis, very low blood sugar, and polyarteritis (inflammation of blood vessels). Also quite rare is liver failure (called fulminant hepatitis) with bleeding from the gastrointestinal tract and brain damage, known as hepatic encephalopathy. Occasionally, the acute phase of hepatitis B or C is more mild yet prolonged, with recovery taking up to 1 year; 5 - 10% of people with this prolonged acute phase go on to develop chronic hepatitis.
After the acute phase, long-term prognosis depends on many factors, including the cause of the hepatitis, whether you go on to become a carrier of type B or develop a chronic form of the disease, and whether you have any other underlying medical problems. about 5 - 10% of people with hepatitis B become carriers, and about 25% of carriers progress to chronic hepatitis. The vast majority of people infected with hepatitis C go on to become life-long carriers, and anywhere from 50 - 90% of these carriers eventually develop chronic hepatitis.
The chronic form of hepatitis can ultimate lead to scarring of the liver (known as cirrhosis) and liver failure. There are two types of chronic hepatitis – chronic active and chronic persistent. The latter is mild and either doesn't get worse or only does so very slowly. Chronic active hepatitis, on the other hand, is much more likely to lead to cirrhosis, permanent damage to the liver. Cirrhosis occurs in 5 - 10% of people with chronic hepatitis from hepatitis B and as many as 20 - 30% of those with chronic hepatitis from hepatitis C. About 14% of people with cirrhosis develop liver cancer.
Hepatitis - viral
Akyuz F, Kaymakoglu S, Demir K, et al., Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastroenterol Belg. 2007;70(1):20-4.
Cohen MR. Herbal and complementary and alternative medicine therapies for liver disease. A focus on Chinese traditional medicine in hepatitis C virus. Clin Liver Dis. 2001;5(2):461-478, vii.
Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig Dis Sci. 2005;50(10):1807-12.
Firpi RJ, Nelson DR. Current and future hepatitis C therapies. Arch Med Res. 2007;38(6):678-90.
Gish RG. Improving outcomes for patients with chronic hepatitis B. Hepatol Res. 2007;37(s1):S67-78.
Gorban EM, Orynchak MA, Virstiuk NG, Kuprash LP, Panteleimonov TM, Sharabura LB. [Clinical and experimental study of spirulina efficacy in chronic diffuse liver diseases.] Lik Sprava. 2000(6):89-93.
Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine (Baltimore). 2001;80(2):134-151.
Isaguliants MG. Functionality of the immune system in patients with chronic hepatitis C: trial by superinfections and vaccinations. Expert Rev Vaccines. 2007;6(4):527-37.
Koshy A, Marcellin P, Martinot M, Madda JP. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver. 2000;20(4):335-339.
Lai MY. Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy. J Gastroenterol Hepatol. 2000;15 Suppl:E130-133.
Langmead L, Rampton DS. Review article: herbal treatment in gastrointestinal and liver disease--benefits and dangers. [Review]. Aliment Pharmacol Ther. 2001;15(9):1239-1252.
Leung NW. Management of viral hepatitis C. J Gastroenterol Hepatol. 2002;17 Suppl: S146-S154.
Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119(1):172-180.
Lieber CS. Liver disease by alcohol and hepatitis C: early detection and new insights in pathogenesis lead to improved treatment. Am J Addict. 2001;10 Suppl:29-50.
Liu JP, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection. Cochrane Database Syst Rev. 2001;(4):CD003183.
Liu JP, McIntosh H, Lin H. Chinese medicinal herbs for asymptomatic carriers of hepatitis B. Cochrane Database Syst Rev. 2001;(2):CD002231.
Martin KW, Ernst E. Antiviral agents from plants and herbs: a systematic review. Antivir Ther. 2003;8(2):77-90.
Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005;12(6):559-67.
McCulloch M, Broffman M, Gao J, Colford JM Jr. Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomized, controlled trials. Am J Public Health. 2002;92(10):1619-1628.
Milliman WB, Lamson DW, Brignall MS. Hepatitis C; a retrospective study, literature review, and naturopathic protocol. Altern Med Rev. 2000;5(4):355-371.
Pellicano R, Fagoonee S, Repici A, Rizzetto M. Hepatitis C virus and human immunodeficiency virus: a dangerous dealing. Panminerva Med. 2007;49(2):79-82.
Pessione F, Ramond MJ, Njapoum C, et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology. 2001;34(1):121-125.
Pianko S, McHutchison JG. Treatment of hepatitis C with interferon and ribaviron. J Gastroenterol Hepatol. 2000;15(6)581-586.
Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases -- a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol. 2005;100(11):2583-91.
Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-2063.
Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology. 2001 Sep;34(3):595-603.
Shahidah KN, Merican I. Chronic hepatitis B and herbal therapy. Med J Malaysia. 2005;60 Suppl B:35-8.
Shimizu I. Antifibrogenic therapies in chronic HCV infection. Curr Drug Targets Infect Disord. 2001;1(2):227-40.
Takagi H, Nagamine T, Abe T, et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat. 2001;8(5):367-371.
Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther. 2007;6(2):146-57.
Wang BE. Treatment of chronic liver diseases with traditional Chinese medicine. JGastroenterol Hepatol. 2000;15 Suppl:E67-E70.